NOX

NOXOPHARM FPO [NOX]
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.
Healthcare · ASX Small Cap
$0.0820 +0.0%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when NOX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track NOX — Free

Active Signals

Bullish Signals

  • MACD momentum is losing steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Drifting lower — down 7.9% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (0.1 quarters)
  • Moderate P/S ratio (7.4x)
  • Strong revenue growth (+50%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +50% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (10.33%/day)
  • Altman Z-Score grey zone (2.78, low-confidence approx)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 12d (+5pts)

Risk Signals

  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-162%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 21% over the past year
Ask Scout AI about NOX
"What's driving NOX today?" "How does NOX compare to peers?" "Key risks for NOX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Pre-IND meeting request with US FDA
NONE Sofr platform versatility shown via childbirth MRFF grant
NONE Fast-tracking of cancer program via novel animal model
MEDIUM SOF-SKN manufacturing begins to ensure clinical trial readi

Recent ASX Announcements

2026-07-06 Pre-IND meeting request with US FDA
2026-07-01 Sofr platform versatility shown via childbirth MRFF grant
2026-06-30 Fast-tracking of cancer program via novel animal model
2026-06-08 SOF-SKN manufacturing begins to ensure clinical trial readi PRICE SENSITIVE
2026-06-01 Change of Director's Interest Notice

Key Metrics

$25.2M
Market Cap
161K
Avg Volume
0.6x
Vol Ratio
$0.05 — $0.14
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-343.6%
ROE
-161.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 64%
LLeader vs LaggardpassRS: 2
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:NOX vs ECSNOX vs VHLNOX vs NTI
Scout Pro — Deeper Analysis for NOX
Try Pro free for 30 days
Share this analysis

Track NOX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required